GSK 'well positioned' for tariffs after beating forecasts Drugmaker GSK has today reaffirmed its outlook for 2025 and said it was "well positioned" to mitigate any hit from potential sector-specific tariffs, after first quarter results beat expectations. Business • 30 Apr
GSK 'well positioned' for tariffs after beating forecasts Drugmaker GSK has today reaffirmed its outlook for 2025 and said it was "well positioned" to mitigate any hit from potential sector-specific tariffs, after first quarter results beat expectations. Business • 30 Apr
Pfizer sells entire Haleon stake for £2.5 billion Drugmaker Pfizer has sold its entire stake in Haleon for about £2.5 billion to institutional investors and the consumer healthcare firm at 385 pence per share, a bookrunner for the deal said today. Business • 19 Mar
Pfizer sells entire Haleon stake for £2.5 billion Drugmaker Pfizer has sold its entire stake in Haleon for about £2.5 billion to institutional investors and the consumer healthcare firm at 385 pence per share, a bookrunner for the deal said today. Business • 19 Mar
GSK beats Q4 earnings estimates, lifts 2031 sales target GSK has today posted a better-than-expected fourth quarter and lifted its 2031 sales target to nearly $50 billion as the British drugmaker aims to invest heavily in its specialty medicines to offset weakness in vaccine. Business • 05 Feb
GSK beats Q4 earnings estimates, lifts 2031 sales target GSK has today posted a better-than-expected fourth quarter and lifted its 2031 sales target to nearly $50 billion as the British drugmaker aims to invest heavily in its specialty medicines to offset weakness in vaccine. Business • 05 Feb
GSK to buy US biotech firm IDRx for up to $1.15 billion British drugmaker GSK said today that it would pay up to $1.15 billion to buy Boston-based biopharmaceutical firm IDRx, which is developing a treatment for a rare type of tumour. Business • 13 Jan
GSK to buy US biotech firm IDRx for up to $1.15 billion British drugmaker GSK said today that it would pay up to $1.15 billion to buy Boston-based biopharmaceutical firm IDRx, which is developing a treatment for a rare type of tumour. Business • 13 Jan
GSK warns of lower 2024 vaccine sales on weaker demand GSK said today its vaccine sales would fall this year, after a weaker-than-expected performance for its respiratory syncytial virus (RSV) and shingles vaccines in the third quarter, sending its shares 4% lower in early trade. Business • 30 Oct 24
GSK warns of lower 2024 vaccine sales on weaker demand GSK said today its vaccine sales would fall this year, after a weaker-than-expected performance for its respiratory syncytial virus (RSV) and shingles vaccines in the third quarter, sending its shares 4% lower in early trade. Business • 30 Oct 24
GSK shares up after settlement of 80,000 Zantac lawsuits Shares of GSK rose as much as 6.5% this morning after the British drugmaker agreed to pay up to $2.2 billion to settle lawsuits in the US that claimed its discontinued heartburn drug Zantac caused cancer. Business • 10 Oct 24
GSK shares up after settlement of 80,000 Zantac lawsuits Shares of GSK rose as much as 6.5% this morning after the British drugmaker agreed to pay up to $2.2 billion to settle lawsuits in the US that claimed its discontinued heartburn drug Zantac caused cancer. Business • 10 Oct 24
GSK lifts profit and sales forecasts after quarterly beat British drugmaker GSK has today raised its annual earnings and sales forecasts after beating second-quarter expectations on strong sales of its cancer and HIV treatments, but its weak vaccines sales and outlook weighed on the shares. Business • 31 Jul 24
GSK lifts profit and sales forecasts after quarterly beat British drugmaker GSK has today raised its annual earnings and sales forecasts after beating second-quarter expectations on strong sales of its cancer and HIV treatments, but its weak vaccines sales and outlook weighed on the shares. Business • 31 Jul 24
GSK ups 2024 profit forecast, says sales growth to slow GSK has today raised its full-year profit forecast on strong demand for vaccines and specialty medicines though it noted sales growth would slow in the second half. Business • 01 May 24
GSK ups 2024 profit forecast, says sales growth to slow GSK has today raised its full-year profit forecast on strong demand for vaccines and specialty medicines though it noted sales growth would slow in the second half. Business • 01 May 24
GSK agrees $1.4 billion Aiolos Bio deal GSK today said it would acquire asthma drug maker Aiolos Bio in a deal worth up to $1.4 billion, as the British drugmaker boosts its growing respiratory diseases portfolio. Business • 09 Jan 24
GSK agrees $1.4 billion Aiolos Bio deal GSK today said it would acquire asthma drug maker Aiolos Bio in a deal worth up to $1.4 billion, as the British drugmaker boosts its growing respiratory diseases portfolio. Business • 09 Jan 24
GSK lifts forecasts on strong launch of RSV vaccine GSK has today raised its full-year profit and sales forecasts for a second time, after better-than-expected quarterly sales of its newly-launched respiratory syncytial virus (RSV) vaccine. Business • 01 Nov 23
GSK lifts forecasts on strong launch of RSV vaccine GSK has today raised its full-year profit and sales forecasts for a second time, after better-than-expected quarterly sales of its newly-launched respiratory syncytial virus (RSV) vaccine. Business • 01 Nov 23
GSK ups 2023 outlook boosted by vaccine, HIV drug sales GSK has today raised its full-year profit and sales guidance after its second-quarter earnings beat expectations, helped by strong sales of its shingles vaccine Shingrix and HIV medicines. Business • 26 Jul 23
GSK ups 2023 outlook boosted by vaccine, HIV drug sales GSK has today raised its full-year profit and sales guidance after its second-quarter earnings beat expectations, helped by strong sales of its shingles vaccine Shingrix and HIV medicines. Business • 26 Jul 23
GSK reaches settlement in US Zantac litigation GSK has said it reached a confidential settlement of a litigation in the United States over claims that the British pharmaceutical giant's heartburn drug Zantac caused cancer. Business • 23 Jun 23
GSK reaches settlement in US Zantac litigation GSK has said it reached a confidential settlement of a litigation in the United States over claims that the British pharmaceutical giant's heartburn drug Zantac caused cancer. Business • 23 Jun 23
GSK beats first-quarter profit, revenue estimates GSK has today beaten expectations for its first-quarter revenue and profit, helped by sales of its blockbuster shingles vaccine Shingrix. Business • 26 Apr 23
GSK beats first-quarter profit, revenue estimates GSK has today beaten expectations for its first-quarter revenue and profit, helped by sales of its blockbuster shingles vaccine Shingrix. Business • 26 Apr 23
GSK reports Q4 profit, sales beat Wall Street estimates GSK has today beat fourth-quarter profit and sales forecasts helped by sales of its blockbuster shingles vaccine Shingrix. Business • 01 Feb 23
GSK reports Q4 profit, sales beat Wall Street estimates GSK has today beat fourth-quarter profit and sales forecasts helped by sales of its blockbuster shingles vaccine Shingrix. Business • 01 Feb 23
GSK lifts full year earnings view again GSK eclipsed analyst estimates for third-quarter earnings today, driven by higher sales of its blockbuster shingles vaccine Shingrix. Business • 02 Nov 22
GSK lifts full year earnings view again GSK eclipsed analyst estimates for third-quarter earnings today, driven by higher sales of its blockbuster shingles vaccine Shingrix. Business • 02 Nov 22
GSK selects Burberry's Brown as its first female CFO Britain's GSK has appointed its first female chief financial officer, Julie Brown, to succeed Iain Mackay, as the drugmaker focuses on its core pharmaceuticals business. Business • 26 Sep 22
GSK selects Burberry's Brown as its first female CFO Britain's GSK has appointed its first female chief financial officer, Julie Brown, to succeed Iain Mackay, as the drugmaker focuses on its core pharmaceuticals business. Business • 26 Sep 22
GSK, Sanofi, Haleon shares stabilise after Zantac slump Shares in GSK, Sanofi and Haleon began to stabilise today after the companies said that nothing material had changed regarding US litigation focused on heartburn drug Zantac. Business • 12 Aug 22
GSK, Sanofi, Haleon shares stabilise after Zantac slump Shares in GSK, Sanofi and Haleon began to stabilise today after the companies said that nothing material had changed regarding US litigation focused on heartburn drug Zantac. Business • 12 Aug 22
GSK spins off consumer health business Haleon British drugmaker GSK has spun off its consumer health business in the biggest listing in Europe for more than a decade. Business • 18 Jul 22
GSK spins off consumer health business Haleon British drugmaker GSK has spun off its consumer health business in the biggest listing in Europe for more than a decade. Business • 18 Jul 22
GSK tops quarterly results expectations GSK has today beaten analyst expectations for its first-quarter results and stood by its forecasts for 2022 on the back of robust uptake of its drugs. Business • 27 Apr 22
GSK tops quarterly results expectations GSK has today beaten analyst expectations for its first-quarter results and stood by its forecasts for 2022 on the back of robust uptake of its drugs. Business • 27 Apr 22
GSK cuts ties with Russia government Britain's GlaxoSmithKline (GSK) has cut ties with the Russian government after sanctions on Moscow for its invasion of Ukraine, according to the drugmaker's website, as GSK's consumer arm also stopped imports of supplements and vitamins. Business • 06 Apr 22
GSK cuts ties with Russia government Britain's GlaxoSmithKline (GSK) has cut ties with the Russian government after sanctions on Moscow for its invasion of Ukraine, according to the drugmaker's website, as GSK's consumer arm also stopped imports of supplements and vitamins. Business • 06 Apr 22
Unilever warns of high inflation, rules out big M&A Unilever has warned of a big hit to profit margins this year as it struggles to pass on higher costs to consumers, and ruled out major acquisitions after investor criticism of its failed pursuit of GlaxoSmithKline's consumer health business. Business • 10 Feb 22
Unilever warns of high inflation, rules out big M&A Unilever has warned of a big hit to profit margins this year as it struggles to pass on higher costs to consumers, and ruled out major acquisitions after investor criticism of its failed pursuit of GlaxoSmithKline's consumer health business. Business • 10 Feb 22
GSK's Covid-related sales hit £1.4 billion GSK racked up £1.4 billion in Covid-related sales in 2021, largely for antibody drug sotrovimab, as it beat quarterly forecasts in its first earnings report since rejecting a bid from Unilever for its consumer arm. Business • 09 Feb 22
GSK's Covid-related sales hit £1.4 billion GSK racked up £1.4 billion in Covid-related sales in 2021, largely for antibody drug sotrovimab, as it beat quarterly forecasts in its first earnings report since rejecting a bid from Unilever for its consumer arm. Business • 09 Feb 22
Govt agrees supply deal with GSK for Covid treatment The Irish Government has agreed a supply deal with pharmaceutical company GSK, which will result in patients here being able to access the drugmaker's new Covid-19 treatment. Business • 27 Jan 22
Govt agrees supply deal with GSK for Covid treatment The Irish Government has agreed a supply deal with pharmaceutical company GSK, which will result in patients here being able to access the drugmaker's new Covid-19 treatment. Business • 27 Jan 22
Unilever won't raise rejected bid for GSK consumer arm Unilever has effectively abandoned its plans to buy GlaxoSmithKline's consumer healthcare business, saying that it would not raise its £50 billion offer that GSK previously rejected. Business • 20 Jan 22
Unilever won't raise rejected bid for GSK consumer arm Unilever has effectively abandoned its plans to buy GlaxoSmithKline's consumer healthcare business, saying that it would not raise its £50 billion offer that GSK previously rejected. Business • 20 Jan 22
GSK says tests show antibody drug works against Omicron GlaxoSmithKline has said that a lab analysis of the antibody-based Covid-19 therapy it is developing with US partner Vir has shown the drug is effective against the new Omicron variant. Business • 02 Dec 21
GSK says tests show antibody drug works against Omicron GlaxoSmithKline has said that a lab analysis of the antibody-based Covid-19 therapy it is developing with US partner Vir has shown the drug is effective against the new Omicron variant. Business • 02 Dec 21
